Fidji Simo

there's a particular kind of attention that lands on someone when they leave a room — especially a room as loud as OpenAI's right now.

Fidji Simo grew up in Sète, a port town in the south of France, and by most accounts carried that outsider's drive across the Atlantic and straight into Silicon Valley. she spent a decade at Facebook, eventually running the app itself — not a small thing, given what that job actually entails, which is managing the attention and behavior of billions of people at once. then in 2021 she moved to Instacart as CEO, steering it through a period that included a public offering and the particular turbulence of a grocery delivery company trying to find its footing in a post-pandemic market. along the way, she co-founded ChronicleBio, a biomedical research company focused on neuroimmune disorders, and became president of CODA, a nonprofit working on complex chronic conditions. she also joined the OpenAI board before, eventually, joining the company itself as CEO of AGI Deployment — which is a title that sounds abstract until you realize it means: figure out how this technology actually lands in the world.

she was, by most reads, Sam Altman's key operator on the applications side. the person thinking not just about what the models can do, but what happens when they meet real infrastructure, real users, real institutions.

and now she's stepping back. not to a competitor, not to a new venture — to her health. the reports are careful about specifics, but the throughline is chronic illness, the kind that doesn't negotiate with your calendar or your org chart. after less than a year in the role, she's moved to an advisory position. Greg Brockman, one of OpenAI's co-founders who had been on an extended leave, is stepping in to take on some of the projects she was leading.

the timing is what makes people pay attention — OpenAI is in an active push toward a potential IPO, and losing a senior executive at that moment is the kind of thing that sharpens questions people were already asking. but the more interesting thing might be the shape of her exit itself. she's not burning bridges. she reportedly told colleagues something about how Mark Zuckerberg had once shared advice about managing her ambition against her health, a detail that made headlines partly because of who said it, but mostly because it points at something real: the people who run these companies are not abstractions, they carry bodies, and those bodies have limits.

what Simo has been building on the side — ChronicleBio, CODA — suggests she's been thinking about this longer than the last few months. neuroimmune disorders aren't a random philanthropic category. they're conditions that are still poorly understood, underfunded, and disproportionately dismissed. that she's been funding and leading research into them while also sitting at the center of the AI industry says something about where her actual attention lives.

she's on the index right now because the news is fresh and the vacancy is real. but the more durable reason is that she's been quietly holding two things at once — the scaling infrastructure of artificial intelligence, and the question of what actually breaks human bodies and minds. stepping back from one doesn't mean abandoning the other. if anything, it might mean the second one is finally getting her full attention.